Idera Makes Leadership Additions
This article was originally published in Scrip
Idera Pharmaceuticals, Inc., has made several leadership additions: appointing Mark J. Cornfeld vice president and medical lead for oncology; Kirsten L. Gruis senior medical director for rare diseases; Tanya N. Lewis vice president of regulatory affairs and quality assurance; and John J. Kirby vice president of corporate accounting. Cornfeld recently held various oncology leadership roles at GlaxoSmithKline and prior to this he was at Johnson & Johnson and Hoffman-LA Roche. Most recently Gruis was director, clinical development at Alnylam Pharmaceuticals and before this she was neuromuscular clinical lead at Pfizer Inc. Lewis has been vice president of regulatory affairs and medical writing at Tesaro, Inc before which she held regulatory roles at Seaside Therapeutics, Vion Pharmaceutical, Millennium Pharmaceuticals and Genzyme Corporation. Finally, Kirby joins Idera from Endo Pharmaceuticals, where most recently he was assistant controller.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.